Gan & Lee Pharmaceuticals. (SHA:603087)
China
· Delayed Price · Currency is CNY 50.33
-0.16 (-0.32%)
May 15, 2025, 3:00 PM CST
SHA:603087 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | May '25 May 14, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Market Capitalization | 30,146 | 26,332 | 31,066 | 18,429 | 39,499 | 74,247 | Upgrade
|
| Market Cap Growth | 13.77% | -15.24% | 68.57% | -53.34% | -46.80% | - | Upgrade
|
| Enterprise Value | 27,801 | 21,268 | 26,918 | 13,463 | 34,935 | 70,382 | Upgrade
|
| Last Close Price | 50.33 | 44.10 | 51.86 | 32.09 | 68.84 | 128.99 | Upgrade
|
| PE Ratio | 35.64 | 42.84 | 91.35 | - | 27.19 | 60.33 | Upgrade
|
| Forward PE | 29.43 | 11.40 | 11.40 | 11.40 | 25.81 | 50.01 | Upgrade
|
| PS Ratio | 8.69 | 8.65 | 11.91 | 10.76 | 10.94 | 22.09 | Upgrade
|
| PB Ratio | 2.66 | 2.38 | 2.89 | 1.92 | 3.89 | 8.31 | Upgrade
|
| P/TBV Ratio | 2.73 | 2.44 | 2.97 | 1.98 | 4.00 | 8.54 | Upgrade
|
| P/FCF Ratio | 196.73 | 272.84 | - | - | 102.30 | 112.63 | Upgrade
|
| P/OCF Ratio | 49.04 | 49.01 | 283.83 | 62.12 | 36.64 | 59.81 | Upgrade
|
| EV/Sales Ratio | 8.01 | 6.98 | 10.32 | 7.86 | 9.67 | 20.94 | Upgrade
|
| EV/EBITDA Ratio | 34.51 | 37.52 | 68.22 | - | 22.24 | 44.70 | Upgrade
|
| EV/EBIT Ratio | 52.31 | 68.43 | 149.52 | - | 25.13 | 49.75 | Upgrade
|
| EV/FCF Ratio | 181.43 | 220.38 | - | - | 90.48 | 106.77 | Upgrade
|
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | Upgrade
|
| Debt / EBITDA Ratio | 0.01 | 0.02 | 0.02 | - | 0.01 | - | Upgrade
|
| Debt / FCF Ratio | 0.08 | 0.14 | - | - | 0.05 | - | Upgrade
|
| Asset Turnover | 0.29 | 0.26 | 0.23 | 0.16 | 0.36 | 0.43 | Upgrade
|
| Inventory Turnover | 0.83 | 0.80 | 0.96 | 0.68 | 0.70 | 0.64 | Upgrade
|
| Quick Ratio | 3.40 | 3.31 | 6.77 | 6.05 | 12.65 | 13.14 | Upgrade
|
| Current Ratio | 4.92 | 4.73 | 7.99 | 6.97 | 14.15 | 14.54 | Upgrade
|
| Return on Equity (ROE) | 7.50% | 5.64% | 3.35% | -4.45% | 15.21% | 17.08% | Upgrade
|
| Return on Assets (ROA) | 2.77% | 1.64% | 1.01% | -3.94% | 8.54% | 11.39% | Upgrade
|
| Return on Capital (ROIC) | 3.00% | 1.78% | 1.11% | -4.27% | 9.09% | 12.27% | Upgrade
|
| Return on Capital Employed (ROCE) | 4.60% | 2.80% | 1.60% | - | 13.40% | 15.60% | Upgrade
|
| Earnings Yield | 2.76% | 2.33% | 1.09% | -2.38% | 3.68% | 1.66% | Upgrade
|
| FCF Yield | 0.51% | 0.37% | -1.43% | -3.73% | 0.98% | 0.89% | Upgrade
|
| Dividend Yield | 0.99% | - | 0.39% | - | 0.44% | 0.31% | Upgrade
|
| Payout Ratio | 50.63% | 68.42% | - | - | 15.46% | 16.30% | Upgrade
|
| Buyback Yield / Dilution | -1.40% | -4.28% | -0.58% | -0.46% | -5.28% | -5.43% | Upgrade
|
| Total Shareholder Return | -0.40% | -4.28% | -0.20% | -0.46% | -4.84% | -5.12% | Upgrade
|
Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.